



## **Collegium to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference**

July 6, 2016

CANTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that management will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Tuesday, July 12, 2016 at 8 a.m. Eastern Time. The conference will be held at Le Parker Meridian New York.

### **About Collegium Pharmaceutical, Inc.**

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx<sup>®</sup> technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.

### **About Xtampza ER**

Xtampza<sup>®</sup> ER is Collegium's first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

**For Important Safety Information Visit, <http://www.xtampzaer.com/>**

### **Contact:**

Douglas Carlson  
Vice President, Corporate Development  
[dcarlson@collegiumpharma.com](mailto:dcarlson@collegiumpharma.com)



Collegium Pharmaceutical, Inc